Lovastatin induces fibroblast apoptosis in vitro and in vivo: A possible therapy for fibroproliferative disorders

American Journal of Respiratory and Critical Care Medicine

Volumn 159, Issue 1, 1999, Pages 220-227

  Tan, Annie ^b   Levrey, Hélène ^b   Dahm, Cornelia ^b   Polunovsky, Vitaly A ^b   Rubins, Jeffrey ^b   Bitterman, Peter B ^a  

^a Pulmonary Division   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; RAS PROTEIN;

ANIMAL CELL; APOPTOSIS; ARTICLE; GRANULATION TISSUE; INFLAMMATION; LUNG FIBROBLAST; LUNG FIBROSIS; NONHUMAN; PRIORITY JOURNAL;

EID: 0013640830     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.159.1.9802104     Document Type: Article

References (47)

1. Bitterman, P. B., and C. A. Henke. 1991. Fibroproliferative disorders. Chest 99:81S-84S.
2. Fukuda, Y., M. Ishizaki, Y. Masuda, G. Kimura, O. Kawanami, and Y. Masugi. 1987. The role of intraalveolar fibrosis in the process of pulmonary structural remodeling in patients with diffuse alveolar damage. Am. J. Pathol 126:171-182.
3. Greco, M. J., J. E. Kemnitzer, J. D. Fox, J. K. Choe, J. Kohn, D. J. Riley, and G. J. Poiani. 1997. Polymer of proline analogue with sustained antifibrotic activity in lung fibrosis. Am. J. Respir. Crit. Care Med. 155:1391-1397.
4. Ferns, G. A. A., E. W. Raines, K. H. Spruge, A. S. Montani, M. A. Reidy, and R. Ross. 1991. Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF. Science 253:1129-1132.
5. Reist, R. H., R. D. Dey, J. P. Durham, Y. Rojanasakul, and V. Castranova. 1993. Inhibition of proliferative activity of pulmonary fibroblasts by tetrandrine. Toxicol. Appl. Pharmacol. 122:70-76.
6. Goldstein, R. H., and A. Fine. 1995. Potential therapeutic initiatives for fibrogenic lung diseases. Chest 108:848-855.
7. Askew, D. S., R. A. Ashmun, B. C. Simmons, and J. L. Cleveland. 1991. Constitutive c-myc expression in an IL-3-dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis. Oncogene 6:1915-1922.
8. Evan, G. I., A. H. Wyllie, C. S. Gilbert, T. D. Littlewood, H. Land, M. Brooks, C. M. Waters, L. Z. Penn, and D. C. Hancock. 1992. Induction of apoptosis in fibroblasts by c-myc protein. Cell 69:119-128.
9. Rao, L., M. Debbas, P. Sabbatini, D. Hockenberry, S. Korsmeyer, and E. White. 1992. The adenovirus E1A proteins induce apoptosis, which is inhibited by the E1B 19kDa and Bcl-2 proteins. Proc. Natl. Acad. Sci. U.S.A. 89:7742-7746.
10. Tan, A., V. A. Polunovsky, and P. B. Bitterman. 1996. The role of cyclin D1 as a downstream effector of translation initiation factor 4E mediated fibroblast survival. In The 36th American Society for Cell Biology Annual Meeting, Vol. 7 (abstract). San Francisco, CA. 191a.
11. Soma, M. R., A. Corsini, and R. Paoletti. 1992. Cholesterol and mevalonic acid modulation in cell metabolism and multiplication. Toxical. Lett. 64-65:1-15.
12. Maltese, W. A. 1990. Posttranslational modification of proteins by isoprenoids in mammalian cells. FASEB J. 4:3319-3328.
13. Kauffmann-Zeh, A., P. Rodriguez-Viciana, E. Ulrich, C. Gilbert, P. Coffer, J. Downward, and G. Evan. 1997. Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB. Nature 385:544-548.
14. Marshall, C. J. 1995. Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell 80:179-185.
15. Chen, B., V. Polunovsky, J. White, B. Blazar, R. Nakhleh, J. Jessurun, M. Peterson, and P. Bitterman. 1992. Mesenchymal cells isolated after acute lung injury manifest an enhanced proliferative phenotype. J. Clin. Invest. 90:1778-1785.
16. Petty, T. L., and D. G. Ashbaugh. 1971. The adult respiratory distress syndrome: clinical features, factors influencing prognosis and principles of management. Chest 60:233-239.
17. Polunovsky, V. A., C. H. Wendt, D. H. Ingbar, M. S. Peterson, and P. B. Bitterman. 1994. Induction of endothelial cell apoptosis by TNFα: modulation by inhibitors of protein synthesis. Exp. Cell Res. 214:584-594.
18. Polunovsky, V. A., I. B. Rosenwald, A. T. Tan, J. White, L. Chiang, N. Sonenberg, and P. B. Bitterman. 1996. Translational control of programmed cell death: eukaryotic translation initiation factor 4E blocks apoptosis in growth-factor-restricted fibroblasts with physiologically expressed or deruglated Myc. Mol. Cell. Biol. 16:6573-6581.
19. Henke, C., P. Bitterman, U. Roongta, D. Ingbar, and V. Polunovsky. 1996. Induction of fibroblast apoptosis by anti-CD44 antibody: implications for the treatment of fibroproliferative lung disease. Am. J. Pathol 149:1639-1650.
20. Jakobisiak, M., S. Bruno, J. S. Skierski, and Z. Darzynkiewicz. 1991. Cell cycle-specific effects of lovastatin. Proc. Natl Acad. Sci. U.S.A. 88:3628-3632.
21. Dvorak, H. F., V. S. Harvey, P. Estrella, L. F. Brown, J. McDonagh, and A. M. Dvorak. 1987. Fibrin containing gels induce angiogenesis: implications for tumor stroma generation and wound healing. Lab. Invest. 57:673-686.
22. Sprugel, K. H., J. M. McPherson, A. W. Clowes, and R. Ross. 1987. Effects of growth factors in vivo: I. Cell ingrowth into porous subcutaneous chambers. Am. J. Pathol. 129:601-613.
23. Lawrence, W. T., J. A. Norton, M. B. Sporn, C. Gorschboth, and G. R. Grotendorst. 1986. The reversal of an Adriamycin induced healing impairment with chemoattractants and growth factors. Ann. Surg. 203:142-147.
24. Rohr, S., F. Toti, C. Brisson, A. Albert, M. Freund, C. Meyer, and J. P. Cazenave. 1992. Quantitative image analysis of angiogenesis in rats implanted with a fibrin gel chamber. Nouv. Rev. Fr. Hematol. 34:287-294.
25. Desager, J.-P., and Y. Horsmans. 1996. Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. Clin. Pharmacokinet. 31:348-371.
26. Baetta, R., R. Paoletti, R. Fumagalli, and M. R. Soma. 1997. Mevalonate modulation of cell proliferation and apoptosis. Oncol. Rep. 4:257-261.
27. Hohl, R. J., and K. Lewis. 1995, Differential effects of monoterpenes and lovastatin on Ras processing. J. Biol. Chem. 270:17508-17512.
28. Sinensky, M., L. A. Beck, S. Leonard, and R. Evans. 1990. Differential inhibitory effects of lovastatin on protein isoprenylation and sterol synthesis. J. Biol. Chem. 265:19937-19941.
29. Polunovsky, V. A., B. Chen, C. Henke, D. Snover, C. Wendt, D. H. Ingbar, and P. B. Bitterman. 1993. Role of mesenchymal cell death in lung remodeling after injury. J. Clin. Invest. 92:388-397.
30. Desmouliere, A., M. Redard, I. Darby, and G. Gabbiani. 1995. Apoptosis mediates the decrease in cellularity during the transition between granulation tissue and scar. Am. J. Pathol. 146:56-66.
31. Duggan, D. E., and S. Vickers. 1990. Physiological disposition of HMG-CoA-reductase inhibitors. Drug Metab. Rev. 22:333-362.
32. Darzynkiewicz, D. B., E. A. Carswell, and L. J. Old. 1984. The cell cycle specific effects of tumour necrosis factor. Cancer Res. 44:83-90.
33. Gibs, J. B., A. Oliff, and N. E. Kohl. 1994. Farnesyltransferase inhibitors: Ras reserach yields a potential cancer therapeutic. Cell 77:175-178.
34. Perez-Sala, D., and F. Mollinedo. 1994. Inhibition of isoprenoid biosynthesis induces apoptosis in human promyelocytic HL-60 cells. Biochem. Biophys. Res. Commun. 199:1209-1215.
35. Han, Z., and J. H. Wyche. 1996. Lovastatin induces apoptosis in a metastatic ovarian tumour cell line. Cell Death Differ. 3:223-228.
36. Padayatty, S. J., M. Marcelli, T. C. Shao, and G. R. Cunningham. 1997. Lovastatin-induced apoptosis in prostate stromal cells. J. Clin. Endocrinol. Metab. 82:1434-1439.
37. Jones, K. D., W. T. Couldwell, D. R. Hinton, Y. Su, S. He, L. Anker, and R. E. Law. 1994. Lovastatin induces growth inhibition and apoptosis in human malignant glioma. Biochem. Biophys. Res. Commun. 205: 1681-1687.
38. Rubins, J. B., T. Greatens, R. A. Kratzke, A. T. Tan, V. A. Polunovsky, and P. B. Bitterman. 1998. Lovastatin induces apoptosis in malignant mesothelioma cells. Am. J. Respir. Crit. Care Med. 157:1616-1622.
39. Kinoshita, T., T. Yokota, K. Arai, and A. Miyajima. 1995. Regulation of Bcl-2 expression by oncogenic Ras protein in hematopoietic cells. Oncogene 10:2207-2212.
40. Gomez, J., C. Martinez-A, B. Fernandez, A. Garcia, and A. Robello. 1996. Critical role of Ras in the proliferation and prevention of apoptosis mediated by IL-2. J. Immunol. 157:2272-2281.
41. Barrington, R. E., M. A. Subler, E. Rands, C. A. Omer, P. J. Miller, J. E. Hundley, S. K. Koester, D. A. Troyer, D. J. Bearss, M. W. Conner, J. B. Gibbs, K. Hamilton, K. S. Koblan, S. D. Mosser, T. J. O'Neill, M. D. Schaber, E. T. Senderak, J. J. Windle, A. Oliff, and N. E. Kohl. 1998. A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis. Mol. Cell. Biol. 18: 85-92.
42. Vincent, T. S., E. Wulfert, and E. Merler. 1991. Inhibition of growth factor signaling pathways by lovastatin. Biochem. Biophys. Res. Commun. 180:1284-1289.
43. McGuire, T. F., X.-Q. Xu, S. J. Corey, G. G. Romero, and S. M. Sebti. 1994. Lovastatin disrupts early events in insulin signaling: a potential mechanism of lovastatin's anti-mitogenic activity. Biochem. Biophys. Res. Commun. 204:399-406.
44. Ortiz, M. B., M. Goin, M. B. G. de Alzaga, S. Hammarstrom, and L. J. de Asua. 1995. Mevalonate dependency of the early cell cycle mitogenic response to epidermal growth factor and prostaglandin F2α in Swiss 3T3 cells. J. Cell. Physiol. 162:139-146.
45. Hengst, L., V. Dulic, J. M. Slingerland, E. Lees, and S. I. Reed. 1994. A cell cycle-regulated inhibitor of cyclin-dependent kinases. Proc. Natl. Acad. Sci. U.S.A. 91:5291-5295.
46. Chong, L. D., A. Traynor-Kaplan, G. M. Bokoch, and M. A. Schwartz. 1994. The small GTP-binding protein Rho regulates a phosphatidyl-inositol 4-phosphate 5-kinase in mammalian cells. Cell 79:507-513.
47. Pietsch, A., W. Erl, and R. L. Lorenz. 1996. Lovastatin reduces expression of the combined adhesion and scavenger receptor CD36 in human monocytic cells. Biochem. Pharmacol. 52:433-439.